Dance Biopharm announced that it has signed an agreement with Phillips-Medisize for development of a connected version of Dance’s Dance 501 insulin soft mist inhaler device. According to the announcement, Phillips-Medisize has already worked on clinical devices for Dance 501, and the new agreement extends their work to potential commercial manufacture.
Dance has said that it is preparing for Phase 3 studies of Dance 501 for the treatment of diabetes. Earlier this year, Dance announced that it had bought back the Asia license for Dance-501 by purchasing the license holder, Harmony Biopharm Limited.
Dance Biopharm Chairman and CEO John Patton said, “We believe our inhaled insulin product is state of the art and well-differentiated from powder based, non-electronic technology. It provides a platform for applying advanced digital medicine for diabetes management. We love Phillips-Medisize and the solutions they offer for this aspect of our product. Inhaled insulin offers the possibility of a cost effective, significant improvement in lifestyle –- ease-of-use and compliance — for diabetic patients all over the world. We believe that our convenient soft-mist product candidate may someday improve the lives of millions of patients.”
Phillips-Medisize Chief Technology Officer Bill Welch commented, “Advancements in drug delivery device technology have created new ways to administer drugs, thereby improving reliability and therapy adherence. Dance’s breathable insulin technology will be a game changer for patients living with diabetes. Working closely with Dance to support a connected health strategy, product development, and manufacturing can enable faster global access to Dance’s innovative insulin delivery solution.”
Read the Dance Biopharm press release.
